Flerie AB (publ) (FLERIE) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning everyone and hello wherever you are in the world. Welcome to the Q1 2025 report presentation for FLIRi. I'm Ted Fjellman and joined with me today Cecilia and the team as well. to take any questions at the end of this session. Let me start straight away by saying it is spring in Europe, and we are, despite all of the market conditions ongoing now, excited about the future, trying to make the best out of a very turbulent time. But let us all remember, just skip over this disclaimer, which I all hope you have read through, that, of course, FLIRI is a long-term investor. We're a biotech and pharma investment company. We have 27 portfolio companies in our portfolio, 74% in private companies. And as you can see from the middle here, we indeed do have a diversified portfolio, which means we can weather the kind of storms that we're seeing on the markets at the moment because we're really developing uh medical technologies are mostly pharmaceuticals through very long-term development programs and that means our sector and what fleary does is uh almost not quite but almost immune to these you know, short term fluctuations, because in the long term, this is really required by society. We have an aging population and they need more and more medical drugs and solutions, the kinds of things that our companies are developing. And of course also the big pharma companies are standing in front of patent cliffs. A lot of their revenue is at stake in the next five years. So the types of companies we're developing are the ones that the big pharma companies are really interested in. And our job at FLIRI is to ensure we optimize the portfolio and ensure that these companies can really develop to inflection points where we either sell them to global pharma or are able to take ...